4/A: MAIA Biotechnology Director Stan Smith Corrects Form 4 Filing After $75,000 Stock and Warrants Purchase

Director Stan Smith files an amended Form 4 to correct the exercisable and expiration dates of warrants and the date of the Securities Purchase Agreement related to a recent transaction.

Summary

• Stan Smith, a director at MAIA Biotechnology, Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the 'Date Exercisable' and 'Expiration Date' of warrants reported in the original Form 4 filed on February 25, 2025.
• The amendment also corrects the date of the Securities Purchase Agreement originally referenced in the footnotes to February 24, 2025.
• On February 24, 2025, Smith purchased 50,000 shares of common stock at $1.50 per share, totaling $75,000.
• He also purchased warrants for 50,000 shares at an exercise price of $1.87.
• The warrants are exercisable beginning February 24, 2026, and expire on February 24, 2031.
• Following the transaction, Smith beneficially owns 1,180,060 shares of common stock indirectly through The Stan V. Smith Trust Dated 1993.
• The warrants are also indirectly owned through the same trust.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The purchase of shares and warrants by a director could be seen as a positive sign, but the amendment itself is neutral.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. Amendments, like this one, are sometimes necessary to correct errors in the original filings.

Key Dates